GTCR seeks EU clearance to buy drugmaker Zentiva
US private-equity firm GTCR has sought EU approval for its acquisition of generic drugmaker Zentiva. The European Commission has set a March 27 deadline to decide on the deal.US private-equity firm...To view the full article, register now.
Already a subscriber? Click here to view full article